Study guide
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone)
Neonatal Pediatric Transport C-NPT
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The C-NPT Exam
About the C-NPT Exam: 2026 Format, Eligibility & Content Outline
2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues
1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations
3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment
2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning
4 Chapter 3: Flight Physiology & Environmental Stressors
3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit
5 Chapter 4: Invasive Procedures & Transport Monitoring
4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines
6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation
5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting
7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies
8 Chapter 7: Neonatal Respiratory Pathologies & Management
7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure
9 Chapter 8: Neonatal Cardiovascular Critical Care
8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure
10 Chapter 9: Neonatal Neurological & Metabolic Crises
9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)
11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care
10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect
12 Chapter 11: Pediatric Respiratory Emergencies
11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia
13 Chapter 12: Pediatric Shock & Cardiovascular Crises
12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass
14 Chapter 13: Pediatric Neurological Emergencies & Trauma
13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness
15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies
14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures
16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies
15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone)
Key Takeaways Explain This Topic AI
Vasoactive selection depends strictly on hemodynamic receptor affinity: alpha-1 stimulation drives systemic vasoconstriction and afterload elevation, beta-1 increases myocardial contractility and heart rate, beta-2 promotes smooth muscle vasodilation, and phosphodiesterase-3 inhibition delivers inotropic support with afterload reduction.
Neonatal myocardium has immature sarcoplasmic reticulum, disorganized myofibrils, and immature sympathetic innervation, so dopamine's indirect (norepinephrine-releasing) inotropic effect may be blunted; direct-acting epinephrine is often preferred when myocardial dysfunction predominates.
Epinephrine is commonly chosen for pediatric cold septic shock (0.05-0.1 mcg/kg/min for beta-1 inotropy; >0.1-1.0 mcg/kg/min for alpha-1 vasoconstriction), while norepinephrine (0.05-1.0 mcg/kg/min) is commonly chosen for warm vasodilatory shock; the Surviving Sepsis Campaign recommends epinephrine or norepinephrine over dopamine without naming one first-line agent.
Milrinone (0.25-0.75 mcg/kg/min) is a non-adrenergic inodilator that decreases both systemic and pulmonary vascular resistance without increasing myocardial oxygen consumption, making it ideal for PPHN and cardiac dysfunction, but transport crews must avoid loading boluses to prevent profound hypotension.
Peripheral extravasation of alpha-adrenergic vasopressors causes severe local ischemic necrosis; immediate antidote treatment requires multiple subcutaneous infiltrations of phentolamine (0.1-0.2 mg/kg up to 5-10 mg diluted in normal saline) into the blanched tissue.
Last updated: September 2026
Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone)
Critical care interfacility transport demands rapid identification and precise hemodynamic stabilization of decompensating circulatory shock. Whether managing a preterm neonate with cardiogenic collapse from closing ductal architecture or an adolescent with hyperdynamic septic shock, transport clinicians must select, calculate, and titrate vasoactive infusions based on complex receptor physiology, developmental pharmacology, and vehicle dynamics.
Adrenergic & Intracellular Receptor Pharmacology
Vasoactive infusions exert their physiological effects through specific adrenergic and intracellular signaling cascades. Mastery of receptor affinities is fundamental to tailoring hemodynamic support to patient-specific pathophysiology:
Alpha-1 ( α 1 \alpha_1 α 1 ) Receptors: Located primarily on vascular smooth muscle. Stimulation activates the phospholipase C pathway, increasing intracellular inositol trisphosphate ( IP 3 \text{IP}_3 IP 3 ) and calcium, producing arterial and venous vasoconstriction. This elevates systemic vascular resistance (SVR), raises mean arterial pressure (MAP), and increases ventricular afterload.
Alpha-2 ( α 2 \alpha_2 α 2 ) Receptors: Predominantly presynaptic autoreceptors in the central and peripheral nervous systems that inhibit endogenous norepinephrine release, attenuating sympathetic outflow.
Beta-1 ( β 1 \beta_1 β 1 ) Receptors: Located in cardiac myocytes, the sinoatrial (SA) node, and atrioventricular (AV) node. Activation stimulates adenylyl cyclase, converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), augmenting protein kinase A (PKA). This enhances intracellular calcium influx during systole, delivering potent positive inotropy (contractility), chronotropy (heart rate), dromotropy (conduction velocity), and lusitropy (myocardial relaxation).
Beta-2 ( β 2 \beta_2 β 2 ) Receptors: Located on bronchial and vascular smooth muscle (especially skeletal and splanchnic beds). Activation increases cAMP, promoting smooth muscle relaxation that results in systemic vasodilation (decreased SVR) and bronchodilation.
Dopaminergic ( DA 1 \text{DA}_1 DA 1 and DA 2 \text{DA}_2 DA 2 ) Receptors: Located in renal, mesenteric, coronary, and cerebral arterial beds. Low-affinity stimulation activates adenylyl cyclase, causing localized vasodilation.
Phosphodiesterase-3 (PDE-3) Inhibition: Intracellular enzyme inhibition preventing cAMP breakdown in cardiac myocytes and vascular smooth muscle, enhancing contractility while driving systemic and pulmonary vasodilation.
Comparative Pharmacodynamics of Transport Vasoactive Infusions
Medication Receptor Affinity Profile Typical Infusion Range Primary Clinical Indications Hemodynamic & Transport Considerations
Epinephrine β 1 > β 2 > α 1 \beta_1 > \beta_2 > \alpha_1 β 1 > β 2 > α 1 (dose-dependent) 0.05 – 1.0 mcg/kg/min Cold septic shock, post-cardiac arrest myocardial dysfunction, anaphylaxis Low dose (0.05–0.1 mcg/kg/min) boosts inotropy; high dose (>0.1–1.0 mcg/kg/min) produces severe α 1 \alpha_1 α 1 vasoconstriction and tachycardia. Induces transient hyperlactatemia via β 2 \beta_2 β 2 -mediated hepatic glycolysis.
Norepinephrine α 1 > β 1 ≫ β 2 \alpha_1 > \beta_1 \gg \beta_2 α 1 > β 1 ≫ β 2 0.05 – 1.0 mcg/kg/min Warm (vasodilatory) septic shock, neurogenic shock, post-bypass vasoplegia Potent systemic vasoconstrictor with modest β 1 \beta_1 β 1 inotropy; restores diastolic blood pressure and coronary perfusion pressure without excessive tachycardia.
Dopamine DA 1 \text{DA}_1 DA 1 (low) → β 1 \rightarrow \beta_1 → β 1 (mid) → α 1 \rightarrow \alpha_1 → α 1 (high) 2 – 20 mcg/kg/min Second-line pediatric shock, symptomatic bradycardia 1–3 mcg/kg/min: renal/mesenteric vasodilation (unproven benefit); 5–10 mcg/kg/min: β 1 \beta_1 β 1 inotropy; 10–20 mcg/kg/min: α 1 \alpha_1 α 1 vasoconstriction. Raises blood pressure in many preterm infants, mainly through vasoconstriction.
Dobutamine β 1 > β 2 > α 1 \beta_1 > \beta_2 > \alpha_1 β 1 > β 2 > α 1 2 – 20 mcg/kg/min Cardiogenic shock, low cardiac output post-cardiac surgery Pure synthetic inotrope with mild peripheral β 2 \beta_2 β 2 vasodilation; reduces afterload while increasing cardiac index. May cause tachycardia and precipitate ventricular arrhythmias.
Milrinone Selective PDE-3 Inhibitor (Non-adrenergic) 0.25 – 0.75 mcg/kg/min PPHN, post-operative congenital heart disease, severe left/right ventricular failure Inodilator: augments contractility, improves diastolic relaxation (lusitropy), reduces SVR and PVR without increasing myocardial MVO 2 \text{MVO}_2 MVO 2 . Bolus must be omitted in transport.
The Neonatal Myocardium & Developmental Limitations of Dopamine
A critical concept on the C-NPT exam is the developmental immaturity of the neonatal and preterm myocardium. Unlike mature pediatric or adult hearts, the neonatal heart operates under distinct structural and physiological constraints:
Myofibrillar Disorganization: Neonatal myocytes contain fewer contractile elements (approximately 30% myofibrils compared to 60% in adults) surrounded by non-contractile mass and collagen. As a result, the neonatal ventricle is stiff, non-compliant, and operates near the peak of its Frank-Starling curve. Stroke volume cannot increase substantially; cardiac output is strictly rate-dependent.
Calcium Handling Immaturity: The sarcoplasmic reticulum (SR) and transverse tubules (T-tubules) are poorly developed. Neonatal myocytes cannot mobilize large intracellular calcium stores and depend almost exclusively on extracellular calcium influx across the sarcolemma. Hypocalcemia rapidly halts neonatal myocardial contractility.
Depleted Sympathetic Innervation: Autonomic sympathetic nerve terminals within the neonatal myocardium are structurally immature and deficient in endogenous norepinephrine stores. Conversely, myocardial adrenergic receptors are fully present and functional.
Why Dopamine May Fail in Neonatal Myocardial Dysfunction
Dopamine exerts its positive inotropic effect through a dual mechanism: direct stimulation of myocardial β 1 \beta_1 β 1 receptors and indirect release of endogenous norepinephrine from sympathetic nerve terminals. Because preterm and term neonates have depleted norepinephrine stores and impaired uptake-storage mechanisms, dopamine acts as a very weak indirect agonist. High doses of dopamine (>10 mcg/kg/min) in neonates stimulate peripheral vascular α 1 \alpha_1 α 1 receptors, raising afterload against an already non-compliant, failing ventricle, which can further reduce cardiac output.
In contrast, epinephrine is a direct-acting catecholamine that binds directly to functional β 1 \beta_1 β 1 and α 1 \alpha_1 α 1 receptors without requiring endogenous neurotransmitter stores. For pediatric septic shock, the 2020 Surviving Sepsis Campaign guidelines suggest epinephrine or norepinephrine rather than dopamine. In neonates, dopamine remains widely used for hypotension and raises blood pressure in many preterm infants, but epinephrine is often preferred when poor myocardial function predominates.
Epinephrine & Norepinephrine in Pediatric Resuscitation & Septic Shock
Septic shock in pediatric patients classically presents along two hemodynamic phenotypes that guide vasoactive selection. The 2020 Surviving Sepsis Campaign pediatric guidelines suggest epinephrine or norepinephrine rather than dopamine and found too little evidence to recommend one over the other, so clinicians choose by physiology:
1. Cold Shock (Low Cardiac Output, High SVR)
Characterized by prolonged capillary refill (>2–3 seconds), mottled cool extremities, weak thready central pulses, narrow pulse pressure, and oliguria. The myocardium is stunned, while compensatory neuroendocrine vasoconstriction elevates SVR.
Usual Agent: Epinephrine (0.05–0.1 mcg/kg/min initially, titrated up to 0.3–0.5 mcg/kg/min).
Mechanism: Low-to-moderate doses activate β 1 \beta_1 β 1 receptors to augment stroke volume and cardiac index, while β 2 \beta_2 β 2 activity balances intense α 1 \alpha_1 α 1 vasoconstriction, improving systemic perfusion.
Exam Warning on Lactate: Epinephrine stimulates hepatic β 2 \beta_2 β 2 receptors, accelerating glycogenolysis and aerobic glycolysis. This routinely generates a benign transient elevation in plasma lactate despite improving organ perfusion. Clinicians must evaluate clinical markers (capillary refill, urine output, central venous oxygen saturation ScvO 2 > 70 % \text{ScvO}_2 > 70\% ScvO 2 > 70% ) rather than treating the lactate number in isolation.
2. Warm Shock (High Cardiac Output, Low SVR)
Characterized by flash capillary refill (<1 second), bounding peripheral pulses, wide pulse pressure, warm extremities, and profound systemic hypotension resulting from cytokine-mediated nitric oxide release and vascular smooth muscle vasoplegia.
Usual Agent: Norepinephrine (0.05–0.1 mcg/kg/min, titrated to 0.5–1.0 mcg/kg/min).
Mechanism: Potent α 1 \alpha_1 α 1 receptor agonism produces intense arterial and venous constriction, restoring SVR, diastolic perfusion pressure, and mean arterial pressure without provoking excessive tachycardia.
Dobutamine & Milrinone: Inotropic Support & Afterload Reduction
When ventricular failure is characterized by severe systolic dysfunction and elevated ventricular afterload (e.g., dilated cardiomyopathy, acute myocarditis, or post-cardiopulmonary bypass), standard vasopressors that raise afterload worsen myocardial work.
Dobutamine (2–20 mcg/kg/min)
A synthetic catecholamine that binds β 1 \beta_1 β 1 and β 2 \beta_2 β 2 receptors in a 3:1 ratio. It increases myocardial contractility while inducing mild peripheral vasodilation. Dobutamine is particularly effective in pediatric cardiogenic shock when blood pressure is preserved, as it increases cardiac index while reducing ventricular wall stress.
Milrinone (0.25–0.75 mcg/kg/min)
Milrinone is a non-adrenergic bipyridine that selectively inhibits phosphodiesterase enzyme type 3 (PDE-3). By blocking the breakdown of cAMP in cardiac myocytes, milrinone increases intracellular calcium during systole (inotropy) and accelerates calcium reuptake into the SR during diastole, markedly improving myocardial relaxation (lusitropy). In systemic and pulmonary vascular smooth muscle, elevated cAMP causes calcium extrusion, producing potent systemic and pulmonary arterial vasodilation (decreasing both SVR and PVR).
Transport Indications: Persistent pulmonary hypertension of the neonate (PPHN), left-to-right shunts with elevated PVR, post-operative cardiac surgical patients, and severe left ventricular failure.
Transport Warning Regarding Loading Bolus: In hospital ICU protocols, a loading dose of 50 mcg/kg is often administered over 10–60 minutes. In critical care transport, the loading bolus is strictly contraindicated or strongly avoided. Rapid bolus administration triggers sudden, unheralded peripheral vasodilation and catastrophic hypotension. Transport clinicians initiate a continuous maintenance infusion at 0.25–0.375 mcg/kg/min and titrate upward slowly without a bolus. Milrinone has an elimination half-life of 2–4 hours (longer in renal insufficiency), necessitating patience during steady-state titration.
Smart Pump Safety, Compatibility & Extravasation Protocols
Transporting unstable infants receiving high-potency vasoactive infusions poses significant mechanical and pharmacological hazards:
Smart Infusion Pump Management
Always utilize dedicated syringe pumps equipped with dose-error reduction systems (DERS) and soft/hard limits programmed specifically for neonatal and pediatric parameters.
Dead Space & Manifold Dynamics: Vasoactive infusions must be connected to the most proximal port of the vascular access device to eliminate carrier fluid dead volume. Unintentional boluses occur when high-flow maintenance fluids flush a manifold containing residual concentrated catecholamines. Conversely, carrier fluids running at very low rates (<1 mL/hr) delay medication arrival to the systemic circulation by tens of minutes.
Ensure dedicated, non-interrupted lines for vasoactive infusions; never administer push medications, blood products, or sodium bicarbonate through an active inotrope line.
Peripheral Extravasation & Phentolamine Management
While central venous access (umbilical venous catheter, PICC, internal jugular) is preferred, transport teams frequently manage patients with peripheral IV lines. Extravasation of alpha-adrenergic agonists (norepinephrine, epinephrine, high-dose dopamine) produces severe local vasoconstriction, tissue ischemia, and full-thickness dermal necrosis.
Clinical Protocol: Extravasation Antidote
If peripheral extravasation occurs:
Stop the infusion immediately ; do not remove the vascular catheter initially.
Gently aspirate as much extravasated drug from the catheter hub as possible, then remove the catheter.
Administer Phentolamine (Regitine), a competitive alpha-adrenergic antagonist: dose 0.1 to 0.2 mg/kg (maximum 5 to 10 mg), reconstituted in 5–10 mL of preservative-free normal saline.
Using a small-gauge (25- to 27-gauge) needle, infiltrate the phentolamine solution subcutaneously in a circumferential pattern directly into the blanched, ischemic tissue. Hyperemia and tissue reperfusion should occur within minutes.